Current Elagolix Endometriosis Activities •Phase III protocol for endometriosis finalized »Endpoints – non-menstrual pelvic pain and dysmenorrhea »Statistical Methods – responder analysis »Trial Design – Two trials, placebo controlled, six-months in duration, safety extension to one year •Investigator meeting held April 2012 •Patient screening begins in May 2012 •Market research »Pharmacoeconomics »Qualitative/Quantitative Research
It also looks like Abbott is being aggressive about moving the uterine fibroids drug forward. They have good reason to believe that this one will also be successful because they already have good data on the ability to reduce bleeding.
The market has recently killed this stock and many many other smallcap biotechs. With the stock rebound expected today, along with the very promising words from the Deutsche Bank conference, I am expecting a healthy recovery starting today. We will see.